← All Research
October 3, 2026·5 min read·Erick Rodriguez, Founder

Before You Ask If It's Safe: Ask If It's What the Label Says

Before asking whether a vial is safe, ask a simpler question: does it contain what the label says, in the amount the label says?

When an Australian testing laboratory analysed 18 vials sold as retatrutide in 2026, one matched its label claim. About a third contained more than the label stated, about a third contained less, and one contained none at all.

In Victoria, Australia, seven people have been hospitalised with acute liver toxicity after injecting products sold as retatrutide. In at least one case, doctors began discussing a liver transplant.

Retatrutide is not approved by any regulator anywhere in the world. There is no legal prescription pathway, no regulated manufacturer, and no one accountable for what is in a vial sold outside a clinical trial.

The Identity Problem Comes Before the Safety Problem

Most conversations about gray-market peptides start with whether a molecule is dangerous. The earlier question is whether the vial contains that molecule, at the strength printed on it.

The testing results answer that question poorly. In the Australian analysis, 17 of 18 vials did not match their label: some over, some under, one empty. A vial that contains double the stated amount and a vial that contains none are both mislabelled, and neither tells the person using it what they are actually taking.

In September, WIRED bought four peptide vials from a Brooklyn bodega and had them tested. None contained the active ingredient on its label. The testing also found only low levels of heavy metals and endotoxins, so the main finding was not contamination. It was that the label meant nothing.

That is the core problem with an unregulated supply. Without identity and strength testing, nobody, including the seller, can say what a given vial contains.

What "Not Approved Anywhere" Means

Retatrutide is an investigational triple hormone receptor agonist (GLP-1, GIP and glucagon) in late-stage trials. Its manufacturer, Eli Lilly, has said it intends to submit an application to the FDA in the first quarter of 2027. Until a regulator approves it, there is:

  • No regulated manufacturer producing it for patients
  • No legal supply chain from synthesis to patient
  • No required potency, identity or sterility testing on what is sold
  • No pharmacovigilance system tracking what happens to people who use it

A label on a vial sold as "retatrutide" establishes only what the seller wants the buyer to believe is inside.

The Victoria Cases

Victoria's Department of Health issued an alert in June 2026 after six cases of acute liver toxicity linked to products sold as retatrutide. By late August the count had reached seven hospitalisations, and Victorian health officials said a contaminated batch of counterfeit product may be circulating in the state.

Writing on October 3, Dr. Hirsh Trivedi, Director of the Metabolic Liver Program at Dell Medical School, University of Texas at Austin, asked clinicians to screen for peptide use in patients presenting with unexplained liver injury. Patients often do not volunteer it, and standard intake forms do not ask.

What caused the injuries has not been established in the public reports. The Victorian findings are case reports and an official alert, not a study, and they cannot say how often this happens.

Regulated Supply Fails Differently

Regulation does not make a supply chain perfect. In September, Centric Compounding issued a nationwide recall of six lots of compounded injectable products (glutathione, Myers' Cocktail and Tri-Immune Boost) after nine adverse event reports. According to the FDA notice, the products were compounded with a glutathione ingredient containing elevated endotoxin levels.

The difference is what happens next. A regulated supplier has to report, recall and answer for the failure, and the recall notice is public. A vial sold outside any regulated system carries none of those obligations, so a bad batch can go unrecognised until patients turn up in hospital.

The Drug Is Real. The Vials Are the Problem.

This post is not about whether retatrutide works in trials. Lilly has reported Phase 3 results, and they are substantial:

  • TRIUMPH-2 (adults with obesity and type 2 diabetes, 80 weeks, published in The Lancet): at the highest dose, the primary analysis counting everyone randomised reported 18.8% mean weight loss, against 5.1% on placebo. Lilly's press release quotes 20.8%, which counts only people who stayed on treatment.
  • TRIUMPH-1 (adults with obesity, or overweight with a related condition, without diabetes, 80 weeks): Lilly reported 25.0% counting everyone randomised and 28.3% among people who stayed on treatment, at the highest dose.

Those results describe the trial drug, manufactured and tested by Lilly and given under trial supervision. They say nothing about the contents of a vial bought online or over a counter, which, on the evidence above, usually does not match its own label.

A Note on How This Travels

Reports like this tend to be read in peptide communities as an attack on the whole category. They are not. The point is narrow: a category with real science behind it is being supplied by sellers with no accountability for what goes into the vials.

The people who most want peptide research taken seriously have the most reason to care about this. Mislabelled vials that put people in hospital are what damage a field's credibility.

1 in 18. That is the number.

Sources

PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical advice. Do not make decisions about starting, stopping, or changing any therapy based on this content. Consult a qualified healthcare provider.

Keep reading with The Peptides Brief

One email a week on what the evidence actually says. No dosing, no hype.

Unsubscribe anytime · Privacy